Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection

Brain, Behavior, and Immunity

Volumn 66, Issue , 2017, Pages 103-110

  Jha, Manish K ^a   Minhajuddin, Abu ^a   Gadad, Bharathi S ^a   Greer, Tracy L ^a   Mayes, Taryn L ^a   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antidepressant; Bupropion; Dopamine; Inflammation; Interleukin 17; Moderator; T cells

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; INTERLEUKIN 17; MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CITALOPRAM; MIANSERIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLACK PERSON; BLOOD BRAIN BARRIER; CAUCASIAN; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DRUG DOSE TITRATION; EDUCATION; EFFECT SIZE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HISPANIC; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MELANCHOLIA; MONOTHERAPY; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SELF-REPORT; RATING SCALE; RHEUMATOID ARTHRITIS; SUICIDAL IDEATION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; COMBINATION DRUG THERAPY; COMPLICATION; INFLAMMATION; MAJOR DEPRESSION; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOMARKERS; BUPROPION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-17; MALE; MIANSERIN; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; VENLAFAXINE HYDROCHLORIDE;

EID: 85025143894     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2017.07.005     Document Type: Article

References (55)

1. Arias, H.R., Santamaría, A., Ali, S.F., Chapter 9 - Pharmacological and Neurotoxicological Actions Mediated By Bupropion and Diethylpropion. International Review of Neurobiology, Vol. 88, 2009, Academic Press, 223–255.
2. Arnow, B.A., Blasey, C., Williams, L.M., Palmer, D.M., Rekshan, W., Schatzberg, A.F., et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am. J. Psychiatr. 172:8 (2015), 743–750.
3. Ascher, J.A., Cole, J.O., Colin, J.N., Feighner, J.P., Ferris, R.M., Fibiger, H.C., et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatr. 56:9 (1995), 395–401.
4. Beurel, E., Harrington, L.E., Jope, R.S., Inflammatory T Helper 17 Cells Promote Depression-like Behavior in Mice. Biol. Psychiatry 73:7 (2013), 622–630.
5. Brustolim, D., Ribeiro-dos-Santos, R., Kast, R.E., Altschuler, E.L., Soares, M.B., A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 6:6 (2006), 903–907.
6. Chen, Y., Jiang, T., Chen, P., Ouyang, J., Xu, G., Zeng, Z., et al. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Res. 188:2 (2011), 224–230.
7. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9:1 (2008), 46–56.
8. Dong, C., TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8:5 (2008), 337–348.
9. Ebbinghaus, M., Gajda, M., Boettger, M.K., Schaible, H.-G., Bräuer, R., The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of Th1 and Th17 responses. Ann. Rheum. Dis. 71:2 (2012), 253–261.
10. Fam, J., Rush, A.J., Burt, T., Chan, E.S., Siddiqui, F.J., Assam, P.N., et al. Thyroid autoimmune antibodies and major depressive disorder in women. Ann. Acad. Med. Singapore 44:8 (2015), 284–289.
11. Fava, M., Rush, A.J., Thase, M.E., Clayton, A., Stahl, S.M., Pradko, J.F., et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Primary Care Companion to J. Clin. Psychiatr. 7:3 (2005), 106–113.
12. Fawcett, J., Rush, A.J., Vukelich, J., Diaz, S.H., Dunklee, L., Romo, P., et al. Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression. Am. J. Psychiatr. 173:2 (2016), 107–111.
13. Felger, J.C., The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications. Curr. Top. Behav. Neurosci., 2016.
14. Felger, J.C., Li, Z., Haroon, E., Woolwine, B.J., Jung, M.Y., Hu, X., et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatr., 2015.
15. Gelenberg, A.J., Freeman, M.P., Markowitz, J.C., Rosenbaum, J.F., Thase, M.E., Trivedi, M.H., Practice guideline for the Treatment of Patients With Major Depressive Disorder Third Edition. Am. J. Psychiatr., 167(10), 2010, 1.
16. Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:11 (2005), 1123–1132.
17. Hennings, J.M., Uhr, M., Klengel, T., Weber, P., Putz, B., Touma, C., et al. RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. Transl. Psychiatr., 5, 2015, e538.
18. Himmerich, H., Schonherr, J., Fulda, S., Sheldrick, A.J., Bauer, K., Sack, U., Impact of antipsychotics on cytokine production in-vitro. J. Psychiatr. Res. 45:10 (2011), 1358–1365.
19. Huppert, J., Closhen, D., Croxford, A., White, R., Kulig, P., Pietrowski, E., et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. 24:4 (2010), 1023–1034.
20. Jha, M.K., Minhajuddin, A., Gadad, B.S., Greer, T., Grannemann, B., Soyombo, A., et al. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology 78 (2017), 105–113.
21. Jin, W., Dong, C., IL-17 cytokines in immunity and inflammation. Emerg. Microbes. Infect., 2, 2013, e60.
22. Karlsson, L., Nousiainen, N., Scheinin, N.M., Maksimow, M., Salmi, M., Lehto, S.M., et al. Cytokine profile and maternal depression and anxiety symptoms in mid-pregnancy—the FinnBrain Birth Cohort Study. Arch. Women's Mental Health 20:1 (2017), 39–48.
23. Kawanokuchi, J., Shimizu, K., Nitta, A., Yamada, K., Mizuno, T., Takeuchi, H., et al. Production and functions of IL-17 in microglia. J. Neuroimmunol. 194:1–2 (2008), 54–61.
24. Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13:10 (2007), 1173–1175.
25. Kim, J.-W., Kim, Y.-K., Hwang, J.-A., Yoon, H.-K., Ko, Y.-H., Han, C., et al. Plasma levels of IL-23 and IL-17 before and after antidepressant treatment in patients with major depressive disorder. Psychiatr. Investig. 10:3 (2013), 294–299.
26. Leung, R., Proitsi, P., Simmons, A., Lunnon, K., Güntert, A., Kronenberg, D., et al. Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS ONE, 8(6), 2013, e64971.
27. Lieberknecht, V., Junqueira, S.C., Cunha, M.P., Barbosa, T.A., de Souza, L.F., Coelho, I.S., et al. Pramipexole, a dopamine D2/D3 receptor-preferring agonist, prevents experimental autoimmune encephalomyelitis development in mice. Mol. Neurobiol., 2016.
28. Liu, A.C., Lee, M., McManus, B.M., Choy, J.C., Induction of endothelial nitric oxide synthase expression by IL-17 in human vascular endothelial cells: implications for vascular remodeling in transplant vasculopathy. J. Immunol. (Baltimore, Md: 1950) 188:3 (2012), 1544–1550.
29. Liu, Y., Ho, R.C.M., Mak, A., The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int. J. Rheum. Dis. 15:2 (2012), 183–187.
30. Martino, M., Rocchi, G., Escelsior, A., Fornaro, M., Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance. Curr. Neuropharmacol. 10:2 (2012), 97–123.
31. Matsunaga, M., How to factor-analyze your data right: do's, don'ts, and how-to's. Int. J. Psychol. Res. 3:1 (2015), 97–110.
32. Melnikov, M., Belousova, O., Murugin, V., Pashenkov, M., Boyko, A., The role of dopamine in modulation of Th-17 immune response in multiple sclerosis. J. Neuroimmunol. 292 (2016), 97–101.
33. Miller, A.H., Raison, C.L., The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16:1 (2015), 22–34.
34. Miller, A.H., Haroon, E., Felger, J.C., Therapeutic implications of brain-immune interactions: treatment in translation. Neuropsychopharmacology 42:1 (2017), 334–359.
35. Park, H., Li, Z., Yang, X.O., Chang, S.H., Nurieva, R., Wang, Y.H., et al. A distinct lineage of CD4T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:11 (2005), 1133–1141.
36. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatr. 70:1 (2013), 31–41.
37. Rush, A.J., Trivedi, M.H., Ibrahim, H.M., Carmody, T.J., Arnow, B., Klein, D.N., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54:5 (2003), 573–583.
38. Rush, A.J., Bernstein, I.H., Trivedi, M.H., Carmody, T.J., Wisniewski, S., Mundt, J.C., et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol. Psychiatry 59:6 (2006), 493–501.
39. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Stewart, J.W., Nierenberg, A.A., Thase, M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354:12 (2006), 1231–1242.
40. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am. J. Psychiatr. 163:11 (2006), 1905–1917.
41. Rush, A.J., Trivedi, M.H., Stewart, J.W., Nierenberg, A.A., Fava, M., Kurian, B.T., et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatr. 168:7 (2011), 689–701.
42. Schatzberg, A.F., DeBattista, C., Lazzeroni, L.C., Etkin, A., Greer, M., Murphy, J., Williams, L.M., ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am. J. Psychiatry 172:8 (2015), 751–759.
43. Shenoy, A.R., Dehmel, T., Stettner, M., Kremer, D., Kieseier, B.C., Hartung, H.P., et al. Citalopram suppresses thymocyte cytokine production. J. Neuroimmunol. 262:1–2 (2013), 46–52.
44. Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., Cleare, A.J., Inflammation and clinical response to treatment in depression: a meta-analysis. Eur. Neuropsychopharmacol. 25:10 (2015), 1532–1543.
45. Swardfager, W., Rosenblat, J.D., Benlamri, M., McIntyre, R.S., Mapping inflammation onto mood: inflammatory mediators of anhedonia. Neurosci. Biobehav. Rev. 64 (2016), 148–166.
46. Toups, M., Trivedi, M.H., Biomarkers and the future of treatment for depression. Cerebrum, 2012, 2012, 6.
47. Trivedi, M.H., Rush, A.J., Ibrahim, H.M., Carmody, T.J., Biggs, M.M., Suppes, T., et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol. Med. 34:1 (2004), 73–82.
48. Trivedi, M.H., Fava, M., Wisniewski, S.R., Thase, M.E., Quitkin, F., Warden, D., et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 354:12 (2006), 1243–1252.
49. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am. J. Psychiatr. 163:1 (2006), 28–40.
50. Uher, R., Tansey, K.E., Dew, T., Maier, W., Mors, O., Hauser, J., et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiatr. 171:12 (2014), 1278–1286.
51. Vichaya, E.G., Hunt, S.C., Dantzer, R., Lipopolysaccharide reduces incentive motivation while boosting preference for high reward in mice. Neuropsychopharmacology 39:12 (2014), 2884–2890.
52. Waisman, A., Hauptmann, J., Regen, T., The role of IL-17 in CNS diseases. Acta Neuropathol. 129:5 (2015), 625–637.
53. Warner-Schmidt, J.L., Vanover, K.E., Chen, E.Y., Marshall, J.J., Greengard, P., Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 108:22 (2011), 9262–9267.
54. Wisniewski, S.R., Rush, A.J., Balasubramani, G.K., Trivedi, M.H., Nierenberg, A.A., Self-rated global measure of the frequency, intensity, and burden of side effects. J. Psychiatr. Practice 12:2 (2006), 71–79.
55. Yao, Z., Fanslow, W.C., Seldin, M.F., Rousseau, A.-M., Painter, S.L., Comeau, M.R., et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3:6 (1995), 811–821.